Mobonib 40 mg (Mobocertinib) Capsules

Mobocertinib is an oral epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that was developed for targeted treatment of certain advanced or metastatic non-small cell lung cancers (NSCLC) carrying EGFR exon 20 insertion mutations. Its historical FDA indication applied to adults whose disease had progressed during or after platinum-based chemotherapy.

Therapeutic effects include:

• Targets abnormal EGFR signaling associated with EGFR exon 20 insertion mutations.
• Inhibits kinase activity involved in tumor-cell growth and survival.
• May reduce signaling pathways that support proliferation of mutation-driven cancer cells.
• Was developed as a targeted treatment option for selected patients with advanced or metastatic NSCLC.
• Its use should be determined by an oncology specialist based on molecular testing, treatment history, and current clinical guidance.

Important: This medicine should not be presented as a general treatment for all types of lung cancer. Its historical indication was specifically linked to EGFR exon 20 insertion mutation-positive NSCLC.

Active Ingredient: Mobocertinib

Strength: 40 mg per capsule

Dosage Form: Hard gelatin capsule

The original FDA labeling describes each 40 mg capsule as containing 40 mg mobocertinib equivalent to 48.06 mg mobocertinib succinate. The capsule shell contains gelatin and titanium dioxide, while the printing ink contains several processing ingredients.

Composition:

• Mobocertinib equivalent to 40 mg
• Mobocertinib succinate equivalent to 40 mg mobocertinib
• Capsule shell: gelatin and titanium dioxide
• Printing ink: shellac and other ink components

For the exact excipient composition of a specific Mobonib 40 product, the current manufacturer's package insert should be checked because formulations and inactive ingredients can vary between products.

Historical adult dosage: The FDA-approved labeling specified 160 mg of mobocertinib taken orally once daily, generally at approximately the same time each day. This corresponds to four 40 mg capsules per dose. The historical labeling allowed administration with or without food.

Administration guidance:

• Take the medicine exactly as prescribed by the treating oncologist.
• Swallow capsules whole with water.
• Do not crush, chew, or open the capsules unless specifically instructed by a healthcare professional.
• Try to take the dose at a consistent time each day.
• Dose modification or interruption may be required if significant adverse reactions occur.

Missed dose: If a dose is missed, follow the current prescribing information and the oncologist's instructions rather than taking an extra dose to compensate.

Important regulatory note: Because the FDA indication for mobocertinib was withdrawn on July 15, 2024, the historical 160 mg once-daily regimen should not be presented on your website as a current universally recommended dose. For a modern product page, label it as “Historical FDA-approved dosage” and advise patients to follow their specialist's current prescription and applicable local regulatory guidance.